Endoglin/CD 105 may not be an optimal tumor endothelial treatment target.

Griffioen, A W; Damen, C A; Blijham, G H; Groenewegen, G

Griffioen, A W; Damen, C A; Blijham, G H; Groenewegen, G.

Breast Cancer Res Treat ; 39(2): 239-42, 1996.

Article in En | MEDLINE | ID: mdl-8872333

Subject(s)

Carcinoma, Renal Cell/blood supply; Endothelium, Vascular/drug effects; Kidney Neoplasms/blood supply; Vascular Cell Adhesion Molecule-1/therapeutic use; Animals; Antigens, CD; Carcinoma, Renal Cell/drug therapy; Endoglin; Endothelium, Vascular/immunology; Female; Humans; Immunotoxins/pharmacology; Kidney Neoplasms/drug therapy; Mice; Receptors, Cell Surface; Vascular Cell Adhesion Molecule-1/adverse effects; Vascular Cell Adhesion Molecule-1/biosynthesis

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Endothelium, Vascular / Carcinoma, Renal Cell / Vascular Cell Adhesion Molecule-1 / Kidney Neoplasms Limits: Animals / Female / Humans Language: En Journal: Breast Cancer Res Treat Year: 1996 Document type: Article Country of publication: Netherlands

Search on Google

Add to My VHL

XML

PubMed Links